LEXINGTON, Mass.--(BUSINESS WIRE)--May 23, 2007 - Synta
Pharmaceuticals Corp., (NASDAQ: SNTA) a biopharmaceutical company
focused on discovering, developing, and commercializing small
molecule drugs to treat severe medical conditions, today announced
that survival and sub-population data from the Phase 2b clinical
trial in metastatic melanoma of the Company's lead oncology drug
candidate, STA-4783, will be presented at the annual meeting of the
American Society of Clinical Oncology (ASCO) in Chicago, Illinois
on Tuesday, June 5, 2007. In this double-blind, randomized,
multi-center trial, patients treated with STA-4783 in combination
with paclitaxel were compared with patients treated with paclitaxel
alone. All patients had stage IV metastatic melanoma.
STA-4783 is a novel, injectable, small molecule investigational
drug candidate that induces a potent oxidative stress response in
cancer cells, driving programmed cell death and enhancing the
activity of anti-cancer agents that act through the mitochondrial
apoptosis pathway, including paclitaxel. In September 2006, Synta
reported positive Phase 2b results for STA-4783 in combination with
paclitaxel in a double-blind, randomized, controlled, multi-center
clinical trial in patients with stage IV metastatic melanoma. In
November 2006, Synta received Fast Track designation from the FDA
for the development of STA-4783 in metastatic melanoma. Synta plans
to initiate a pivotal Phase 3 clinical trial for STA-4783 in
mid-2007 and one or more Phase 2 studies in other cancer
indications later in the year.
The schedule and meeting places for the presentation, together
with the abstract numbers, are listed below:
Poster Presentations
Tuesday, June 5, 2007 at 8:00 a.m. to 12:00 p.m. - Poster
Presentation: 17
Abstract No. 8528
"Subgroup analysis of efficacy and safety analysis of a
randomized, double-blinded controlled phase 2 study of STA-47
'"/>
Page: 1 2 3 Related medicine technology :1.
Synta Presents Results for STA-4783 in Metastatic Melanoma Showing
Improvement in Overall Survival2.
Synta Pharmaceuticals to Host Conference Call Today3.
Positive ZIO-201 Interim Phase II Sarcoma Data Presented at
European Society for Medical Oncology4.
European Society for Medical Oncology (ESMO) Presents Data from the
Clinical Trial of MediGenes Cancer-Killing Virus in Press
Conference5.
Gloucester Pharmaceuticals Reports Positive Interim Phase II Data
on Romidepsin for T-Cell Lymphomas at the 2007 American Society of
Clinical Oncology Annual Meeting6.
MGI Pharma Summarizes Data Presented at the 2007 American Society
of Clinical Oncology (ASCO) Annual Meeting7.
MGI Pharma, Inc. Summarizes Data Presented at the 2007 American
Society of Clinical Oncology (ASCO) Annual Meeting8.
Hana Biosciences Presents Data On Two Programs At the American
Society of Clinical Oncology Annual Meeting9.
Access and Somanta Announce Data to be Presented on Angiolix at
ASCO Oncology Conference10.
Pharmion to Present Clinical Data on Commercial and Pipeline
Products at 2007 American Society of Clinical Oncology (ASCO)
Meeting11.
CytImmune Presents Positive CYT-6019 Data During the American
Society of Clinical Oncology Annual Meeting in Chicago